活动时间：2017-03-21 ~ 2017-03-22
活动地点：上海市浦东新区锦江汤臣洲际大酒店
活动类型：商务论坛
主办单位：DELIVER
活动简介：
About APRDL 2017
The Pharma and Biotech sectors are at a pivotal point in their evolution. Pharmaceutical companies are likely to continue to increase the percentage of their R&D work that is outsourced in Asia. This trend will continue to be driven by the pursuit of Open Innovation in University-Industrial Partnership, Improving R&D cost efficiency as well as effectiveness. Beyond generating one-off savings, the emphasis will move to streamlining the outsourcing operating model, risk management, complexity management and lean process improvement. Doing more R&D with less and smartly.
The Asia Pharma R&D Leaders Summit 2017 ( APRDL 2017 ) will bring in fresh perspectives and scientific advancement on popular therapeutic areas in Neurodegenerative Diseases; Cancer, Diabetes and metabolic diseases which big pharma R&D are heavily investing in Asia. The new perspective will be discussed in parallel with pharma partnering models, licensing opportunities, risk management approaches, outsourcing strategies, Precision Medicine, IP management and latest pharma research advancement on sequencing, biomarkers, preclinical imaging, data management to optimize your pharma R&D cost efficiency and gain competitiveness in Asia. Come and join Asia Pharma R&D Leaders 2017 – the most premier pharma R&D event in China with Asia perspectives:
With over 50 speakers and estimation to bring over 250 pharma R&D professionals, the key conference topics will cover:
-- Asian Strategies: How Big Pharma and Biotech companies manage their R&D activities
-- How can companies drive maximum value from M&A and licensing deals
-- Government initiatives in China 13th 5 years’ plan benefit for your research projects in China
-- Explore mass in-licensing opportunities in Asia emerging markets in response to new world R&D order
-- Novel Technologies and Approaches for Drug Discovery
-- Precision Medicine & Personalized Healthcare
-- Research Ethics & Ethical Approval
-- Develop new business models in 2017 and beyond for pharma R&D geared toward cost efficiency and ROI improvement
-- Navigate Asia market trends for heavily invested therapeutics areas: Oncology, Neurodegenerative and Metabolic diseases
-- Lay foundations for effective partnership with top CROs, Biotech and Academia
-- Tapping into Funding & Investment Opportunities in Pharmaceutical R&D in Asia
-- Challenges of Conducting Clinical Trials in APAC, Regulatory Requirements & IRB Approval Process
-- Open Innovation in University-Industrial Partnership for BioMedical Technology Development
-- Personalized anticancer drug discovery & development in Asia
On behalf of the committee, we sincerely hope primary discussions, topics and invitees would come across your scientific and strategic interests And the whole summit will be consisted of keynote speeches, panel/roundtable discussions, open Q&A sessions, booth and poster exhibition and cozy, guided networking sessions for all professionals and management who are working for the pharmaceutical research and development programs in Asia.
会议流程：
Day 1 TUESDAY March 21, 2017
08:40 大会主席开幕致辞
加强并优化亚太药物研发合作创新
08:50 全球药物研发领袖圆桌讨论：未来5年全球制药企业在中 国的投入与合作创新
这场全球药物研发领袖圆桌旨在探讨未来中国的药物研发创新;我们邀请全球药物研发领袖(来自跨国药厂全球总部的战略决策层)参与圆桌讨论并且分享他们未来在中国的研发投入和战略合作发展
09:40 区域药物研发领袖圆桌讨论：促进中国与亚太研发创新 -- 从跨国药厂亚太药物研发领袖;本土药厂的研发决策层和研发外包组织的视角讨论未来药企在中国的创新与合作
10:10 通过整体的测试平台来加速药物研发 ( 药明康德 赞助 )
10:40 茶歇，展台访问与交流
11:10 通过并优化全球的战略合作与投资，加速药物研发创新
Uwe Schoenbeck,
全球药物研发外部创新合作高级副总裁, 辉瑞全球研发首席科学官
– 辉瑞制药 ( 美国总部)
11:40 Singapore A*Star: 研发和技术企业在开放式创新中扮演的角色
Benjamin Seet
生物药品委员会执行总监, 新加坡 A*Star
开放式创新与合作机遇
13:30 学术机构与跨国制药企业的合作：从全球的视角看亚太区域 的合作创新机遇
利民,
葛兰素史克中国研发中心总经理及全球神经系统药物研发部总裁 –
全球部门总裁级别，中国研发中心总经理
14:00 通过大学与制药企业的开放式创新合作来加速生物医疗技 术的发展
陳東敏
院長/部長/講席教授; 北京大學產業技術研究院 | 北京大學科技 開發部 | 北京大學前沿交叉學科研究院
14:30 将最高精尖的科学带到中国 – 从跨国药厂的角度谈 第十三个
五年计划内的中国药物创新和投资机遇
石斌,
外部研发合作与创新总监，安进亚太药物研发中心
15:00 茶歇，展台访问与交流
糖尿病的新药开发与治疗
15:30 研究并且评估多肽和蛋白对二型糖尿病的治疗
Soren Tullin, 诺和诺德生物化学技术集团副总裁 ( 丹麦总部 )
16:00 结合灵长类动物的糖尿病模型应用于新型药物的研究
汪亦欣, 心血管和代谢疾病部高级副总裁，冠科医药
16:30 在亚太进行药物和医疗器械临床试验的挑战
Timothy Low, 首席执行官，新加坡 FARRER PARK HOSPITAL
17:00 第一天会议结束
Day 2 WEDNESDAY MARCH 22, 2017
针对二型糖尿病的新药研究专题
08:50 开幕致辞
Soren Tullin,
诺和诺德生物化学技术集团副总裁 ( 丹麦总部 )
09:00胃旁路手术对二型糖尿病治疗的研究
吴家睿，研究员，研究组长，博士生导师，中国科学院上海生命科学研究院，生物化学与细胞生物学研究所
09:30 中国本土制药企业在糖尿病研究中的进展
张连山，研发中心总裁，江苏恒瑞制药
10:00 学术单位对中国糖尿病基础研究做出的贡献
王明伟，复旦大学药学院院长，国家新药筛选中心主任
10:30 茶歇，展台访问与交流
11:00 糖尿病基础研究和转换科学
11:30 二型糖尿病研究小组讨论
12:00 午宴，展台访问与交流
中国生物医药研发的合作与专利转让
13:30再鼎医药的中国研发与未来合作发展战略
Samantha Du, 董事长兼首席执行官. 再鼎医药
14:00索元生物 – 精准医学, 生物标志物的研究和个性化医疗
的中国发展
Wen Luo, 首席执行官. 索元生物
14:30茶歇，展台访问与交流
15:00 圆桌讨论：第十三个五年规划下的中国生物制药企业的发展
15:45 圆桌讨论：第十三个五年规划下的中国生物制药企业的发展
沈健中，服务部门副总裁，法务长，阿斯利康
李彩辉，首席知识产权保护官，国家抗体研究中心，三生国健制药
16:15 案例分享：恒瑞制药的全球研发策略
张连山，全球研发创新中心总裁，江苏恒瑞药业
17:00 闭幕致辞
联系方式：+86 21 6172 6970
About APRDL 2017
The Pharma and Biotech sectors are at a pivotal point in their evolution. Pharmaceutical companies are likely to continue to increase the percentage of their R&D work that is outsourced in Asia. This trend will continue to be driven by the pursuit of Open Innovation in University-Industrial Partnership, Improving R&D cost efficiency as well as effectiveness. Beyond generating one-off savings, the emphasis will move to streamlining the outsourcing operating model, risk management, complexity management and lean process improvement. Doing more R&D with less and smartly.
The Asia Pharma R&D Leaders Summit 2017 ( APRDL 2017 ) will bring in fresh perspectives and scientific advancement on popular therapeutic areas in Neurodegenerative Diseases; Cancer, Diabetes and metabolic diseases which big pharma R&D are heavily investing in Asia. The new perspective will be discussed in parallel with pharma partnering models, licensing opportunities, risk management approaches, outsourcing strategies, Precision Medicine, IP management and latest pharma research advancement on sequencing, biomarkers, preclinical imaging, data management to optimize your pharma R&D cost efficiency and gain competitiveness in Asia. Come and join Asia Pharma R&D Leaders 2017 – the most premier pharma R&D event in China with Asia perspectives:
With over 50 speakers and estimation to bring over 250 pharma R&D professionals, the key conference topics will cover:
-- Asian Strategies: How Big Pharma and Biotech companies manage their R&D activities
-- How can companies drive maximum value from M&A and licensing deals
-- Government initiatives in China 13th 5 years’ plan benefit for your research projects in China
-- Explore mass in-licensing opportunities in Asia emerging markets in response to new world R&D order
-- Novel Technologies and Approaches for Drug Discovery
-- Precision Medicine & Personalized Healthcare
-- Research Ethics & Ethical Approval
-- Develop new business models in 2017 and beyond for pharma R&D geared toward cost efficiency and ROI improvement
-- Navigate Asia market trends for heavily invested therapeutics areas: Oncology, Neurodegenerative and Metabolic diseases
-- Lay foundations for effective partnership with top CROs, Biotech and Academia
-- Tapping into Funding & Investment Opportunities in Pharmaceutical R&D in Asia
-- Challenges of Conducting Clinical Trials in APAC, Regulatory Requirements & IRB Approval Process
-- Open Innovation in University-Industrial Partnership for BioMedical Technology Development
-- Personalized anticancer drug discovery & development in Asia
On behalf of the committee, we sincerely hope primary discussions, topics and invitees would come across your scientific and strategic interests And the whole summit will be consisted of keynote speeches, panel/roundtable discussions, open Q&A sessions, booth and poster exhibition and cozy, guided networking sessions for all professionals and management who are working for the pharmaceutical research and development programs in Asia.
会议流程：
Day 1 TUESDAY March 21, 2017
08:40 大会主席开幕致辞
加强并优化亚太药物研发合作创新
08:50 全球药物研发领袖圆桌讨论：未来5年全球制药企业在中 国的投入与合作创新
这场全球药物研发领袖圆桌旨在探讨未来中国的药物研发创新;我们邀请全球药物研发领袖(来自跨国药厂全球总部的战略决策层)参与圆桌讨论并且分享他们未来在中国的研发投入和战略合作发展
09:40 区域药物研发领袖圆桌讨论：促进中国与亚太研发创新 -- 从跨国药厂亚太药物研发领袖;本土药厂的研发决策层和研发外包组织的视角讨论未来药企在中国的创新与合作
10:10 通过整体的测试平台来加速药物研发 ( 药明康德 赞助 )
10:40 茶歇，展台访问与交流
11:10 通过并优化全球的战略合作与投资，加速药物研发创新
Uwe Schoenbeck,
全球药物研发外部创新合作高级副总裁, 辉瑞全球研发首席科学官
– 辉瑞制药 ( 美国总部)
11:40 Singapore A*Star: 研发和技术企业在开放式创新中扮演的角色
Benjamin Seet
生物药品委员会执行总监, 新加坡 A*Star
开放式创新与合作机遇
13:30 学术机构与跨国制药企业的合作：从全球的视角看亚太区域 的合作创新机遇
利民,
葛兰素史克中国研发中心总经理及全球神经系统药物研发部总裁 –
全球部门总裁级别，中国研发中心总经理
14:00 通过大学与制药企业的开放式创新合作来加速生物医疗技 术的发展
陳東敏
院長/部長/講席教授; 北京大學產業技術研究院 | 北京大學科技 開發部 | 北京大學前沿交叉學科研究院
14:30 将最高精尖的科学带到中国 – 从跨国药厂的角度谈 第十三个
五年计划内的中国药物创新和投资机遇
石斌,
外部研发合作与创新总监，安进亚太药物研发中心
15:00 茶歇，展台访问与交流
糖尿病的新药开发与治疗
15:30 研究并且评估多肽和蛋白对二型糖尿病的治疗
Soren Tullin, 诺和诺德生物化学技术集团副总裁 ( 丹麦总部 )
16:00 结合灵长类动物的糖尿病模型应用于新型药物的研究
汪亦欣, 心血管和代谢疾病部高级副总裁，冠科医药
16:30 在亚太进行药物和医疗器械临床试验的挑战
Timothy Low, 首席执行官，新加坡 FARRER PARK HOSPITAL
17:00 第一天会议结束
Day 2 WEDNESDAY MARCH 22, 2017
针对二型糖尿病的新药研究专题
08:50 开幕致辞
Soren Tullin,
诺和诺德生物化学技术集团副总裁 ( 丹麦总部 )
09:00胃旁路手术对二型糖尿病治疗的研究
吴家睿，研究员，研究组长，博士生导师，中国科学院上海生命科学研究院，生物化学与细胞生物学研究所
09:30 中国本土制药企业在糖尿病研究中的进展
张连山，研发中心总裁，江苏恒瑞制药
10:00 学术单位对中国糖尿病基础研究做出的贡献
王明伟，复旦大学药学院院长，国家新药筛选中心主任
10:30 茶歇，展台访问与交流
11:00 糖尿病基础研究和转换科学
11:30 二型糖尿病研究小组讨论
12:00 午宴，展台访问与交流
中国生物医药研发的合作与专利转让
13:30再鼎医药的中国研发与未来合作发展战略
Samantha Du, 董事长兼首席执行官. 再鼎医药
14:00索元生物 – 精准医学, 生物标志物的研究和个性化医疗
的中国发展
Wen Luo, 首席执行官. 索元生物
14:30茶歇，展台访问与交流
15:00 圆桌讨论：第十三个五年规划下的中国生物制药企业的发展
15:45 圆桌讨论：第十三个五年规划下的中国生物制药企业的发展
沈健中，服务部门副总裁，法务长，阿斯利康
李彩辉，首席知识产权保护官，国家抗体研究中心，三生国健制药
16:15 案例分享：恒瑞制药的全球研发策略
张连山，全球研发创新中心总裁，江苏恒瑞药业
17:00 闭幕致辞
联系方式：+86 21 6172 6970
最近参与
- 暂无报名，期待您的参与
......
0条评论
